An update on community-acquired pneumonia in adults

Compr Ther. 2000 Winter;26(4):283-93. doi: 10.1007/s12019-000-0031-8.

Abstract

Community-acquired pneumonia (CAP) is a leading cause of morbidity and mortality, despite effective therapies. Guidelines for CAP management vary widely in their approach. Resistance of S pneumoniae to penicillins and other antibiotics has prompted evaluation of the new fluoroquinolones.

Publication types

  • Review

MeSH terms

  • Adult
  • Aged
  • Anti-Bacterial Agents / therapeutic use
  • Anti-Infective Agents / therapeutic use
  • Community-Acquired Infections
  • Fluoroquinolones
  • Humans
  • Lactams
  • Macrolides
  • Middle Aged
  • Pneumonia / diagnosis
  • Pneumonia / drug therapy*
  • Pneumonia / microbiology
  • Pneumonia / prevention & control
  • Practice Guidelines as Topic
  • Tetracyclines
  • United States

Substances

  • Anti-Bacterial Agents
  • Anti-Infective Agents
  • Fluoroquinolones
  • Lactams
  • Macrolides
  • Tetracyclines